Oleg Nodelman is the Founder and Managing Director of EcoR1 Capital. See contact routes.
Oleg Nodelman is the Founder and Managing Director of EcoR1 Capital, a San Francisco-based biotech-focused investment advisory firm he established in 2013 after serving as a portfolio manager at BVF Partners for 11 years. His investment thesis targets companies across all stages of research and development within the healthcare, life sciences, and oncology sectors, with a focus on the United States. Unlike many peers, Nodelman avoids betting on the underlying science, instead selecting companies with a margin of safety derived from intellectual property, unreleased products, or partnerships with major pharmaceutical developers. His firm manages discretionary assets exceeding $3.9 billion and holds significant positions in public biotech companies, including Apellis Pharmaceuticals Inc., Zymeworks, Galapagos NV, and AnaptysBio. Nodelman currently serves on the boards of directors for Zymeworks, Galapagos NV, and AnaptysBio, leveraging his deep roots in scientific communities to guide these firms. A distinctive point of his approach is his value-oriented strategy that prioritizes financial safety over scientific speculation, a philosophy he has articulat
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in San Francisco.
Investors like Oleg Nodelman · Full investor directory · Investor access · Company funding database